Patient-Reported Outcome and Quality of Life Data on Maintenance Therapy

In patients who refuse or are ineligible for radical cystectomy, the gemcitabine intravesical system may be given after unsuccessful BCG treatment.

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

Changes in FKSI-15 scores from baseline indicated more favorable HRQOL outcomes with the benmelstobart combo vs sunitinib in advanced ccRCC.

Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.

Patients with muscle-invasive bladder cancer with a positive Signatera test displayed a significant improvement in disease-free and overall survival.

Results from the SunRISe-1 trial showed that TAR-200 monotherapy achieved a complete response rate of 82.4% in patients with BCG-unresponsive NMIBC.